Abnormal epigenetic changes during differentiation of human skeletal muscle stem cells from obese subjects by Davegårdh, Cajsa et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Abnormal epigenetic changes during differentiation of human skeletal muscle stem
cells from obese subjects
Davegårdh, Cajsa; Broholm, Christa; Perfilyev, Alexander; Henriksen, Tora; García-Calzón,
Sonia; Peijs, Lone; Hansen, Ninna Schiøler; Volkov, Petr; Kjøbsted, Rasmus; Wojtaszewski,
Jørgen; Pedersen, Maria; Pedersen, Bente Klarlund; Ballak, Dov B; Dinarello, Charles A;
Heinhuis, Bas; Joosten, Leo A B; Nilsson, Emma; Vaag, Allan; Scheele, Camilla; Ling,
Charlotte
Published in:
BMC Medicine
DOI:
10.1186/s12916-017-0792-x
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Davegårdh, C., Broholm, C., Perfilyev, A., Henriksen, T., García-Calzón, S., Peijs, L., ... Ling, C. (2017).
Abnormal epigenetic changes during differentiation of human skeletal muscle stem cells from obese subjects.
BMC Medicine, 15, [39]. https://doi.org/10.1186/s12916-017-0792-x
Download date: 03. Feb. 2020
RESEARCH ARTICLE Open Access
Abnormal epigenetic changes during
differentiation of human skeletal muscle
stem cells from obese subjects
Cajsa Davegårdh1 , Christa Broholm2, Alexander Perfilyev1, Tora Henriksen3, Sonia García-Calzón1, Lone Peijs3,
Ninna Schiøler Hansen2, Petr Volkov1, Rasmus Kjøbsted4, Jørgen F. P. Wojtaszewski4, Maria Pedersen3,
Bente Klarlund Pedersen3, Dov B. Ballak5,6, Charles A. Dinarello6,7, Bas Heinhuis7, Leo A. B. Joosten7, Emma Nilsson1,
Allan Vaag2,9, Camilla Scheele3,8† and Charlotte Ling1*†
Abstract
Background: Human skeletal muscle stem cells are important for muscle regeneration. However, the combined
genome-wide DNA methylation and expression changes taking place during adult myogenesis have not been
described in detail and novel myogenic factors may be discovered. Additionally, obesity is associated with low
relative muscle mass and diminished metabolism. Epigenetic alterations taking place during myogenesis might
contribute to these defects.
Methods: We used Infinium HumanMethylation450 BeadChip Kit (Illumina) and HumanHT-12 Expression BeadChip
(Illumina) to analyze genome-wide DNA methylation and transcription before versus after differentiation of primary
human myoblasts from 14 non-obese and 14 obese individuals. Functional follow-up experiments were performed
using siRNA mediated gene silencing in primary human myoblasts and a transgenic mouse model.
Results: We observed genome-wide changes in DNA methylation and expression patterns during differentiation of
primary human muscle stem cells (myoblasts). We identified epigenetic and transcriptional changes of myogenic
transcription factors (MYOD1, MYOG, MYF5, MYF6, PAX7, MEF2A, MEF2C, and MEF2D), cell cycle regulators, metabolic
enzymes and genes previously not linked to myogenesis, including IL32, metallothioneins, and pregnancy-specific
beta-1-glycoproteins. Functional studies demonstrated IL-32 as a novel target that regulates human myogenesis,
insulin sensitivity and ATP levels in muscle cells. Furthermore, IL32 transgenic mice had reduced insulin response
and muscle weight. Remarkably, approximately 3.7 times more methylation changes (147,161 versus 39,572) were
observed during differentiation of myoblasts from obese versus non-obese subjects. In accordance, DNMT1
expression increased during myogenesis only in obese subjects. Interestingly, numerous genes implicated in
metabolic diseases and epigenetic regulation showed differential methylation and expression during differentiation
only in obese subjects.
Conclusions: Our study identifies IL-32 as a novel myogenic regulator, provides a comprehensive map of the
dynamic epigenome during differentiation of human muscle stem cells and reveals abnormal epigenetic changes
in obesity.
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resistance
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Background
Human skeletal muscle stem cells, called satellite cells,
are quiescent, but activated in response to muscle injury
[1] and resistance exercise training [2]. Activation of sat-
ellite cells represents a muscle repair mechanism. Upon
activation, these cells proliferate and a subpopulation,
myoblasts, differentiates and fuses with existing muscle
fibers or other differentiating muscle cells [3], thus con-
tributing to multinucleated muscle fibers. The process,
called myogenesis, is strictly controlled by timely ex-
pression of a network of myogenic regulatory factors
(MRFs), including MYOD, MYF5, MYOG, and MYF6, to-
gether with myocyte enhancer factors 2 (MEF2s) [4, 5].
However, it is possible that novel myogenic factors that
regulate differentiation of human myoblasts into myo-
tubes, and consequently muscle cell function, can be dis-
covered. Additionally, although epigenetic mechanisms
such as DNA methylation are known to regulate cell dif-
ferentiation and cell-specific gene expression, the epige-
nome and transcriptome of human adult myogenesis is far
from defined [6–8].
Obesity is a major risk factor for developing muscular
insulin resistance, a condition preceding type 2 diabetes
[9], and is associated with decreased relative muscle
mass and impaired muscle metabolism [10, 11]. Satellite
cells reside under the basal lamina of the muscle fibers
and are thus exposed to the same environmental factors
as the muscle fibers. We have previously reported that
in vivo properties, including decreased insulin sensitivity
and growth factor signaling, are preserved when human
satellite cells from obese subjects with type 2 diabetes are
isolated and differentiated to myotubes in vitro [12–14].
Therefore, we hypothesized that obesity-dependent
epigenetic modifications are established in human sat-
ellite cells and potentially affect myogenesis in obese
individuals.
Of note, factors such as high fat diet, exercise, and
aging have previously been shown to alter the DNA
methylation pattern in human skeletal muscle [15–19].
Additionally, muscle biopsies isolated from monozygotic
twin pairs discordant for type 2 diabetes and body mass
index (BMI) exhibit differential DNA methylation [20].
Based on this background, we aimed to study changes
in the genome-wide DNA methylation and gene expres-
sion patterns during human adult myogenesis, i.e. differ-
entiation of activated primary human muscle stem cells
(myoblasts) from healthy subjects into myotubes, and
also examine if obesity affects the epigenetic and tran-
scriptional changes that take place during this process.
To address these questions we (1) studied changes in the
genome-wide DNA methylation and expression patterns
during differentiation of primary human myoblasts into
myotubes in healthy subjects; (2) performed functional
follow-up experiments of some identified candidate
genes previously not known to affect myogenesis in
order to find novel targets that regulate muscle regener-
ation and function; and (3) examined if the epigenetic
and transcriptional changes that take place in human
myoblasts during differentiation into myotubes are dif-
ferent in obese compared with non-obese subjects.
Methods
Primary human muscle stem cell isolation and culture of
myoblasts
Primary muscle stem cells (satellite cells) were isolated
from human vastus lateralis biopsies. Myoblasts were
harvested when less than 50% confluent (Additional file
1: Figure S1A). See Additional file 1: Supplemental
Methods for details of myoblast culture and differentiation.
DNA methylation and mRNA expression arrays
DNA methylation was analyzed using Infinium Human-
Methylation450 BeadChip (Illumina, San Diego, CA,
USA). mRNA expression was analyzed using HumanHT-
12 Expression BeadChip (Illumina). See Additional file 1:
Supplemental Methods for details.
Statistical analysis
Two-tailed t-tests were used to compare clinical charac-
teristics between the groups. Comparison of DNA
methylation and expression data between myoblasts and
myotubes were analyzed with paired Wilcoxon signed
rank tests and for array data adjusted for multiple testing
with false discovery rate (FDR) analysis. Spearman corre-
lations were used to correlate gene expression and DNA
methylation. Number of correlations expected by chance
was calculated as number of tests times 0.05. Data from
gene silencing experiments were analyzed with paired t-
tests and log-transformed values were used for qPCR
data. Mouse data were analyzed with Mann–Whitney U
tests. Distributions were analyzed with χ2 tests and
Bonferroni-corrected when feasible. To compare DNA
methylation and mRNA expression array data between
non-obese and obese subjects we used a linear regres-
sion analysis including obesity, age, and sex as co-
variates. A FDR less than 5% (q < 0.05) was applied. See
Additional file 1: Supplemental Methods for more details
of materials and methods.
Results
Human muscle stem cells
Human muscle stem cells (satellite cells) were isolated
from skeletal muscle biopsies obtained from 14 healthy
non-obese and 14 obese subjects. Their clinical charac-
teristics are described in Table 1. Isolated satellite cells
were expanded and differentiated from myoblasts into
myotubes [13]. Cells were harvested as proliferating
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myoblasts and as fully differentiated myotubes (Additional
file 1: Figure S1A).
To evaluate myogenic purity of the cultured cells, we
assessed their cell surface marker expression by flow cy-
tometry analysis. To discriminate myogenic cells from
non-myogenic cells, we used CD56, which is expressed
on myogenic cells, and CD31 and CD45, which are
expressed on endothelial and hematopoietic cells, re-
spectively [21]. All cell cultures were negative for CD31
and CD45 and all cell cultures were positive for CD56;
there was no significant difference between the non-
obese and obese groups in the percentage of gated single
cells expressing CD56 (Additional file 1: Figure S1B–D).
Changes in the global DNA methylation pattern during
differentiation of primary human myoblasts into
myotubes of healthy subjects
To examine if epigenetic changes take place during hu-
man myogenesis, we examined the genome-wide DNA
methylation pattern in human myoblasts and myotubes
from 14 healthy non-obese subjects using the Infinium
HumanMethylation450 BeadChip. An overview of com-
parisons performed in this study is presented in Fig. 1a.
After quality control, DNA methylation data were ob-
tained for a total of 477,226 CpG sites in myoblasts and
myotubes. The analyzed CpG sites have been annotated
to different gene regions based on their genomic loca-
tion and in relation to CpG islands [22]. To examine the
global methylation level for myoblasts and myotubes, we
calculated the average level of DNA methylation in these
gene regions (Fig. 1b). The highest level of methylation
(48–63%) was found distant from promoter regions
(gene body and 3’UTR) and in intergenic regions,
whereas regions close to the transcription start site
(TSS1500, TSS200, 5‘UTR and 1st exon) were least meth-
ylated (12–26%). Interestingly, the average methylation
levels for TSS1500, TSS200, 5’UTR and 1st exon were sig-
nificantly increased after differentiation (q < 0.05). When
investigating global methylation in CpG island regions,
the CpG islands (15%) and the shores (36–37%) were least
methylated and their average methylation levels increased
significantly after differentiation (q < 0.05). The shelves
and the open sea had an average methylation level of ap-
proximately 60% and were not altered during myogenesis.
Of note, all genomic regions with a relatively low degree
of methylation increased significantly after differentiation,
suggesting that epigenetic regulation in these regions
might play an important role during human myogenesis.
Changes in DNA methylation of individual CpG sites
during differentiation of primary human myoblasts into
myotubes of healthy subjects
We next tested if DNA methylation of any individual
CpG site changed in myoblasts versus myotubes from
the 14 healthy non-obese subjects. Indeed, DNA methy-
lation of a large number of individual CpG sites (39,572)
changed significantly during differentiation (FDR less
than 5%; q < 0.05). The significant sites are annotated to
13,639 unique genes and intergenic regions (Additional
file 2: Table S1). Our findings reflect dominant de novo
methylation as the majority of these sites (92%, 36,541
sites) had increased methylation, whereas only 8% (3031
sites) had decreased methylation after differentiation
(Fig. 1c). CpG sites with increased methylation after dif-
ferentiation generally had a low degree of methylation in
myoblasts, whereas CpG sites with decreased methyla-
tion had a relatively high degree of methylation in
myoblasts (Fig. 1d). The largest absolute change in
Table 1 Clinical characteristics of study participants
Non-obese
(N = 14)
Obese
(N = 14)
P value
Men/Women 7/7 8/6
Age, years 54.2 ± 6.8 50.2 ± 6.2 1.3 × 10−1
BMI, kg/m2 24.7 ± 2.4 35.1 ± 2.8 5.1 × 10−11
Weight, kg 74.5 ± 14.2 111.3 ± 9.0 1.2 × 10−9
Hip circumference, cm 100.6 ± 4.7 119.6 ± 6.9 5.7 × 10−9
Waist circumference, cm 85.9 ± 10.2 116.1 ± 8.6 6.2 × 10−9
Android fat mass, kg 1.7 ± 7.1 4.9 ± 1.0 4.3 × 10−10
Gynoid fat mass, kg 4.0 ± 1.3 7.0 ± 2.0 6.5 × 10−5
Whole body fat mass, kg 20.0 ± 6.0 42.7 ± 8.7 1.7 × 10−8
Whole body fat-free
mass, kg
51.4 ± 13.3 63.9 ± 11.9 1.4 × 10−2
Fasting glucose,
mmol/L
4.8 ± 0.6 5.0 ± 0.4 2.3 × 10−1
2-h glucose,
mmol/La
5.2 ± 1.4 5.5 ± 1.4 5.6 × 10−1
Fasting insulin,
pmol/L
32.1 ± 13.3 92.7 ± 30.3 3.8 × 10−7
2-h insulin, pmol/La 230.1 ± 155.3 441.9 ± 287.0 2.4 × 10−2
HOMA-IR 1.0 ± 0.5 3.0 ± 1.1 1.8 × 10−6
HOMA-β, % 74.4 ± 26.7 184.4 ± 74.8 2.4 × 10−5
P-Cholesterol-total, mmol/L 5.5 ± 1.0 5.2 ± 0.8 4.3 × 10−1
P-Cholesterol-HDL,
mmol/L
1.7 ± 0.5 1.3 ± 0.3 1.7 × 10−2
P-Cholesterol-LDL, mmol/L 3.3 ± 0.9 3.3 ± 0.6 9.8 × 10−1
Systolic blood pressure,
mmHg
134.3 ± 12.0 138.5 ± 18.1 4.7 × 10−1
Diastolic blood pressure,
mmHg
85.6 ± 9.5 91.6 ± 9.1 9.8 × 10−1
Pulse, beats/min 59.5 ± 12.4 66.6 ± 8.4 8.6 × 10−11
VO2 max per kg,
mL/min/kg
32.6 ± 11.4 22.2 ± 4.4 3.8 × 10−3
Data are presented as mean ± SD. Two-tailed t-tests were used for
statistical calculations
aMeasured during a 2-h oral glucose tolerance test
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methylation and fold-change were 16.5% and 2.05, re-
spectively (Additional file 2: Table S1).
Interestingly, several key myogenic transcription factors,
including PAX7, MRFs, and MEF2s, had numerous CpG
sites with significant changes in DNA methylation before
versus after differentiation (Additional file 2: Table S1),
suggesting that changes in DNA methylation contribute
to the regulation of human myogenesis. The three most
significant CpG sites for each of these myogenic transcrip-
tion factors are shown in Fig. 1e. Of note, PAX7 showed
differential methylation of 24 of 81 analyzed CpG sites, all
but one with increased methylation, and 7 of 9 analyzed
Fig. 1 The human methylome before versus after differentiation of human primary myoblasts. a An illustrative description of the study design
and comparisons performed in cells of both non-obese and obese subjects. b Global DNA methylation was calculated as the average degree of
methylation for all analyzed CpG sites before (n = 14) and after (n = 14) differentiation of myoblasts of non-obese subjects based on Illumina’s
annotations to different gene regions and CpG island regions. Data are presented as mean ± SEM. Total number of sites per region: TSS1500,
83,650; TSS200, 62,369; 5’UTR, 64,909; 1st Exon, 39,236; Body, 172,275; 3’UTR, 19,349; Intergenic, 116,209. c A pie chart showing the number and
proportions of individual CpG sites with significantly increased and decreased methylation, respectively, in human myoblasts compared with
myotubes (q< 0.05) of non-obese subjects (n= 14). d Proportions of significant CpG sites with a certain degree of methylation before differentiation
compared with the proportions of all analyzed sites. e DNA methylation of the three most significant CpG sites annotated to key myogenic transcription
factors in human myoblasts versus myotubes of non-obese subjects. f Global DNA methylation was calculated as the average degree of methylation for
all analyzed non-CpG sites before and after differentiation in non-obese subjects based on Illumina’s annotations to different gene region and CpG island
regions. Data are presented as mean ± SEM. TSS, proximal promoter, defined as 200 bp (base pairs) or 1500 bp upstream of transcription start site; UTR,
untranslated region; CpG island, 200 bp (or more) stretch of DNA with a C + G content greater than 50% and an observed CpG/expected CpG in excess
of 0.6; Shore, the flanking region of CpG islands, 0–2000 bp; Shelf, regions flanking island shores, i.e., covering 2000–4000 bp distant from the CpG island.
* q< 0.05
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CpG sites annotated to MYF5 showed significantly in-
creased methylation after differentiation.
We next performed KEGG pathway analysis using
Webgestalt [23] to identify biological pathways with
enrichment of genes that exhibited differential DNA
methylation during myogenesis. Genes with one or more
differentially methylated CpG site(s) were significantly
enriched in 27 KEGG-pathways (Table 2 and Additional
file 2: Table S1). Among the significant pathways were
MAPK signaling, cell cycle, oxidative phosphorylation,
regulation of actin cytoskeleton, TGF-β signaling, and
calcium signaling, together supporting the development
of a functional myotube [4].
MicroRNA (miRNA) is another epigenetic mechanism
known to regulate gene transcription and DNA methyla-
tion may further regulate miRNA expression [24]. A
number of miRNAs has also been shown to influence
myogenesis [25]. Here, we found significant methylation
changes of 225 CpG sites annotated to 157 different
miRNA genes during myogenesis (Additional file 2:
Table S1), including 17 of the 60 miRNA identified by
Dmitriev et al. [25].
Methylation of non-CpG sites during myogenesis
Although DNA methylation in the human genome
mainly takes place on cytosines in CpG sites, cytosines
Table 2 Significantly enriched KEGG pathways among differentially methylated genes between myoblasts and myotubes
Pathway (total number of genes in pathway) Observed/Expected
number of genes
P value q value
Non-obese subjects
Pathways in cancer (325) 321/295 9.8 × 10−10 2.2 × 10−7
Metabolic pathways (1112) 1060/1009 3.3 × 10−9 3.7 × 10−7
Focal adhesion (200) 199/182 7.6 × 10−8 4.3 × 10−6
Endocytosis (200) 199/182 7.6 × 10−8 4.3 × 10−6
MAPK signaling pathway (267) 260/242 1.4 × 10−5 5.0 × 10−4
Ubiquitin mediated proteolysis (134) 133/122 3.3 × 10−5 1.1 × 10−3
Neurotrophin signaling pathway (127) 126/115 6.2 × 10−5 1.8 × 10−3
Protein processing in endoplasmic reticulum (165) 162/150 1.0 × 10−4 1.8 × 10−3
Lysosome (121) 120/110 1.0 × 10−4 1.8 × 10−3
Cell cycle (124) 123/113 8.1 × 10−5 1.8 × 10−3
Oxidative phosphorylation (119) 118/108 1.0 × 10−4 1.8 × 10−3
Regulation of actin cytoskeleton (211) 205/192 2.0 × 10−4 2.9 × 10−3
TGF-beta signaling pathway (84) 84/76 3.0 × 10−4 3.8 × 10−3
Axon guidance (129) 127/117 4.0 × 10−4 4.8 × 10−3
Phosphatidylinositol signaling system (78) 78/71 5.0 × 10−4 5.7 × 10−3
Purine metabolism (162) 158/147 6.0 × 10−4 6.5 × 10−3
Calcium signaling pathway (176) 171/160 8.0 × 10−4 7.9 × 10−3
Pyrimidine metabolism (98) 97/89 8.0 × 10−4 7.9 × 10−3
Adipocytokine signaling pathway (68) 68/62 1.4 × 10−3 1.3 × 10−2
p53 signaling pathway (68) 68/62 1.4 × 10−3 1.3 × 10−2
Wnt signaling pathway (149) 145/135 1.5 × 10−3 1.3 × 10−2
ErbB signaling pathway (87) 86/79 2.1 × 10−3 1.7 × 10−2
Melanogenesis (101) 99/92 3.5 × 10−3 2.6 × 10−2
Inositol phosphate metabolism (57) 57/52 4.0 × 10−3 2.9 × 10−2
Peroxisome (79) 78/72 4.3 × 10−3 3.0 × 10−2
mTOR signaling pathway (52) 52/47 6.5 × 10−3 4.2 × 10−2
Spliceosome (127) 123/115 7.0 × 10−3 4.4 × 10−2
Obese subjects
Pathways in cancer (325) 325/311 4.3 × 10−7 9.8 × 10−5
Metabolic pathways (1112) 1086/1063 2.0 × 10−4 2.3 × 10−2
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followed by another base than guanine can also be
methylated, by the so called non-CpG methylation.
Methylation of non-CpG sites has previously been found
in stem cells [26] and we therefore tested if methylation
of these sites changed during myogenesis. The average
methylation level of the analyzed non-CpG sites in-
creased significantly for all gene and CpG island regions
after differentiation (Fig. 1f ). Additionally, methylation
of 665 individual non-CpG sites (60% of the analyzed
sites) changed significantly and all showed increased
methylation after differentiation (q < 0.05) (Additional
file 2: Table S1).
Changes in the transcriptome during differentiation of
primary human myoblasts into myotubes of healthy
subjects
We proceeded to evaluate the genome-wide transcriptome
changes characterizing human myogenesis. Complete
mRNA data were obtained from 13 healthy non-obese
subjects. We found significant expression changes of a
large number of transcripts (7699 with FDR < 5%) cor-
responding to 6305 unique genes before versus after
differentiation (Additional file 3: Table S2); 45% of
these transcripts were upregulated and 55% were
downregulated.
Importantly, several key myogenic transcription factors
were differentially expressed between myoblasts and
myotubes (Fig. 2a). For example, PAX7, MYOD1, MYF5,
and MYF6 showed significantly decreased expression,
while MYOG, MEF2A, MEF2C, and MEF2D showed
increased expression after differentiation (Fig. 2a and
Additional file 3: Table S2). In accordance, all of these
genes exhibited differential DNA methylation during
myogenesis (Fig. 1e and Additional file 2: Table S1).
To further dissect what cellular events the differentially
expressed genes are involved in, Gene Set Enrichment
Analysis (GSEA) [27] was applied. Among downregulated
genes, we identified 17 significant gene sets, including
gene sets related to DNA replication and nucleotide bio-
synthesis, i.e., the cell cycle (Fig. 2b and Additional file 3:
Table S2). Additionally, 25 gene sets were significant
among upregulated genes, including extracellular matrix
receptor interactions, calcium signaling, and several
pathways involved in cellular metabolism (Fig. 2c and
Additional file 3: Table S2), altogether confirming that the
cells developed from proliferating myoblasts into metabol-
ically active myotubes (Additional file 1: Figure S1A). Not-
ably, many genes regulating the cell cycle (Fig. 2d) and
protein turnover showed significantly altered expression
during myogenesis, reflecting withdrawal from the cell
cycle before differentiation. The negative regulators of the
cell cycle, CDKN1A and CDKN1C, were upregulated while
many cyclins (CCNA2, CCNB1, CCNB2, and CCNE2) and
cyclin-dependent kinases (CDK1, CDK2, and CDK6) were
downregulated after differentiation. Moreover, numerous
genes important for muscle contraction, such as myosin
light chain (MLC) and heavy chain (MHC) (Fig. 2e),
troponin, and actin, genes regulating storage, release and
reuptake of calcium ions, as well as genes involved in oxi-
dative phosphorylation (Fig. 2f) were upregulated after
differentiation.
Since skeletal muscle is an endocrine organ [28] we
also examined if the expression pattern of a number of
cytokines, growth factors, and their receptors changed
during differentiation (Fig. 2g). The regulation pattern of
these genes may reflect autocrine properties of skeletal
muscle cells, which are crucial for muscle repair and de-
velopment [1].
Identification of gene families with novel regulation
patterns during myogenesis
Remarkably, we also identified several gene families previ-
ously not known to affect myogenesis, including metal-
lothioneins, pregnancy-specific beta-1-glycoproteins (PSGs),
and chorionic gonadotropin beta polypeptides (CGBs)
(Fig. 3a–c). Interestingly, all significant genes in these
families were highly expressed in myoblasts and strongly
downregulated after differentiation. While two of the gene
families, PSG and CGB, are produced by trophoblasts
during pregnancy [29, 30], their expression has never been
reported in myoblasts.
Identification of transcription factor binding motifs of
importance for myogenesis
To identify transcription factors potentially driving tran-
scriptional changes during myogenesis, we used PSCAN
[31] and JASPAR [32]. Here, we searched for overrepresen-
tation of specific transcription factor binding sequences
among the differentially expressed genes. Recognition se-
quences for 48 transcription factors were significantly
enriched (PBonferroni < 0.05) (Additional file 3: Table S2) and
18 of these did also themselves show differential expression
between myoblasts and myotubes (Fig. 3d), including
members in the SP/KLF family and E2F transcription fac-
tor family.
Overlapping changes in DNA methylation and mRNA
expression during myogenesis
Epigenetic modifications can affect gene expression [33];
hence, we looked for genes that had changes in both
DNA methylation and expression after differentiation.
When comparing myoblasts and myotubes from healthy
subjects, 4285 genes had significant differences in both
expression and DNA methylation of one or more CpG
site(s) (Fig. 1a, Table 3 and Additional file 4: Table S3).
These include the MRFs (Figs. 1e and 2a), many of the
cell cycle genes (Figs. 2d and 3e), metallothioneins
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(Fig. 3a and f), and the transcription factors identified
with PSCAN (Fig. 3d and g).
We then performed correlation analyses between ex-
pression and methylation of corresponding CpG sites for
the 4285 genes that had significant differences in both
(Additional file 4: Table S3). Here, we found 1236 and
998 correlations between expression and methylation in
myoblasts and myotubes, respectively (Additional file 4:
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Table S3), which is more than expected by chance based
on χ2 tests (688 correlations with P < 0.05).
Using a luciferase assay, we continued to functionally
study if DNA methylation affects the transcriptional ac-
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and expression during myogenesis. MCM10, which
encodes a maintenance protein involved in DNA replica-
tion, was selected for this experiment as it showed in-
creased methylation of several sites in the promoter
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differentiation (Fig. 3h). A CpG-free luciferase expres-
sion vector containing 2000 bp of the MCM10 promoter
was either methylated in vitro with SssI or mock-
methylated and transfected into cells. In line with our
myotube data, we found that methylation of the
MCM10 promoter resulted in decreased transcriptional
activity (Fig. 3i).
Functional follow-up experiments identified IL-32 as a
novel regulator of myogenesis and insulin sensitivity
Although it is well established that some key proteins
regulate the myogenesis in human muscle cells [4], we
hypothesized that there may be some additional pro-
teins, not yet discovered, affecting the differentiation of
myoblasts into myotubes and consequently muscle cell
function. Genes previously not known to affect myoblast
differentiation and which showed both altered expres-
sion and DNA methylation during myogenesis were
therefore selected for functional follow-up studies.
The first selected candidate gene, IL32 (encoding the
cytokine Interleukin (IL)-32), showed a large increase in
expression together with altered methylation in human
myotubes compared with myoblasts (Fig. 4a).
IL-32 has previously been implicated in inflammatory
diseases and cancer, but its role in myogenesis or muscle
function remains unknown [34]. We next evaluated how
the mRNA and protein expression patterns of IL-32
changed over time during differentiation of myoblasts
into myotubes. Here, we found a significant increase in
IL-32 expression 3 days after induction of differentiation
and then a further increase after 7 days of differentiation
(Fig. 4b and Additional file 1: Figure S2A). To assess
whether IL-32 affects myogenesis or muscle function, we
transfected primary human myoblasts with siRNA
against IL32 upon induction of differentiation. The cells
were harvested at three time points – at 0 hours and 3
or 7 days after start of differentiation and siRNA trans-
fection. An overview of the siRNA experiment is shown
in Additional file 1: Figure S2B. Silencing of IL32 re-
sulted in significantly decreased IL-32 mRNA and pro-
tein levels both 3 and 7 days after transfection with
siRNA (Fig. 4c and Additional file 1: Figure S2C).
We continued to investigate the effects of IL32
silencing on gene expression using microarray analysis.
We found 1231 unique genes that were differentially
expressed between IL32 silenced myotubes and cells
treated with non-targeting siRNAs (si-SCR) (q < 0.05,
Additional file 5: Table S4). We then applied GSEA and
among the significant upregulated gene sets were several
muscle-specific pathways (Fig. 4d and Additional file 5:
Table S4). We also found increased expression of
MYOD1 and MEF2C as well as several MHCs and MLCs
in IL32 silenced cells (Fig. 4e), suggesting a negative role
for IL-32 in myogenesis. Additionally, downregulated
gene sets were related to amino acid and nucleotide
turnover (Fig. 4d and Additional file 5: Table S4). Inter-
estingly, a number of genes involved in ATP generation,
e.g., in the citric acid cycle, the respiratory chain as well as
creatine kinases were also upregulated, together with
PPARGC1A, a transcriptional regulator of genes influen-
cing energy metabolism (Fig. 4e).
As the microarray data indicated metabolic alterations
in the IL32 silenced cells, we proceeded to dissect the
impact of IL-32 in myotubes. In line with our microarray
data, we found increased ATP levels in IL32 silenced
cells (Fig. 4f ). Moreover, IL-32-deficient myotubes ex-
hibited increased insulin-stimulated AKT phosphoryl-
ation, as a measure of insulin sensitivity, at serine 473
(Ser473) and threonine 308 (Thr308) compared to con-
trol cells (si-SCR) (Fig. 4g). There was also a trend to-
wards increased AKT phosphorylation at Thr308 at
baseline (P = 0.11) (Fig. 4g). However, we could not de-
tect any differences in glycogen synthase or TBC1D4
phosphorylation levels (data not shown).
These in vitro data in myotubes propose that IL-32
may contribute to impaired insulin sensitivity and me-
tabolism. We subsequently tested if IL32 expression in
human skeletal muscle biopsies correlates with measures
of insulin sensitivity analyzed in vivo using HOMA-IR in
a cohort previously described [17]. Interestingly, IL32
expression in muscle biopsies taken from middle-aged
healthy men correlated positively with HOMA-IR (Fast-
ing glucose (mmol/L) × Fasting insulin (mU/L)/22.5),
further supporting a negative impact of IL-32 on insulin
sensitivity (Fig. 4h).
To better understand the function of IL-32 on muscle
growth and insulin sensitivity in vivo, we used transgenic
mice expressing human IL32 in skeletal muscle as well
as other tissues [35]. IL32 transgenic (IL32tg) and con-
trol (WT) mice were fed a Paigen high fat diet (HFD)
[36] or control diet for 18 weeks, after which tibialis an-
terior and soleus muscle were excised; Fig. 4i shows the
design of the mouse study. Despite similar body weight,
IL32tg mice had significantly lighter tibialis muscle than
WT after 18 weeks on HFD, both in absolute and rela-
tive terms (Fig. 4j–l). Moreover, IL32tg mice on HFD
had significantly higher glucose levels and responded
less well to insulin after a 20 minutes insulin tolerance
test versus WT (Fig. 4m, n). On the other hand, their
fasting glucose levels were reduced. No differences in
muscle weight or insulin sensitivity were observed for
mice on control diet (data not shown), nor were any dif-
ferences in glucose levels observed during an oral glu-
cose tolerance test or in food intake in any of the groups
(data not shown).
We proceeded to investigate gene expression in tibialis
anterior from IL32tg and WT mice on a HFD by micro-
array. We found 1821 unique genes that were
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differentially expressed with P < 0.05, but none with q <
0.05 (Additional file 5: Table S4), including MYH2,
TNNT3, and CKMT2. GSEA revealed oxidative phos-
phorylation, citric acid cycle and pyruvate metabolism
among significantly downregulated gene sets in IL32tg
mice (Fig. 4o and Additional file 5: Table S4), which is in
line with human myotube data where IL32-deficient cells
had increased OXPHOS gene expression and ATP levels.
Also in line with human myotube data, ribosome was
the only upregulated gene set in IL32tg mice (Fig. 4o
and Additional file 5: Table S4).
To further follow-up our AKT findings in human
myotubes and the impaired insulin sensitivity in IL32tg
mice, fresh soleus muscles from mice in each group
were incubated in vitro for 30 minutes with and without
insulin. IL32tg mice on HFD showed decreased Akt
phosphorylation at Thr308 both with or without insulin
stimulation (Fig. 4p), which is in accordance with our
human myotube data (Fig. 4g). However, we could not
detect any differences in Akt phosphorylation at Ser473
or ATP levels in soleus between the groups (data not
shown).
In summary, these in vitro and in vivo experiments
from both human and mouse support IL-32 as a novel
player affecting myogenesis and muscle function.
Another novel candidate gene, ARPP21 (encoding
cAMP-regulated phosphoprotein), was selected for func-
tional follow-up experiments based on its massive upregu-
lation and altered methylation in myotubes compared to
myoblasts (Additional file 1: Figure S2D). ARPP21 showed
a modest but significant increase in expression 3 days after
induction of differentiation and then a dramatic increase
after 7 days of differentiation (Additional file 1: Figure
S2E). To study the influence of ARPP-21 on myogenesis,
we used the same siRNA silencing set-up as for IL32 but
with fewer read-outs as presented in Additional file 1:
Figure S2B. Silencing of ARPP21 reduced MYOG ex-
pression at day 3 of differentiation and reduced TNNI1
(encoding Troponin I Type 1) expression levels both at
days 3 and 7 (Additional file 1: Figure S2F-G), propos-
ing that the increased ARPP21 expression during late
myogenesis may function to stimulate structural proteins
like troponin.
Two additional candidate genes, SMAD6 and PLAC8,
were selected for follow-up experiments based on their
massive downregulation and altered methylation during
myogenesis (Additional file 1: Figure S2H, I). Here, we
used siRNA to study whether reduced expression of
SMAD6 and PLAC8 in myoblasts affects proliferation,
initiation of myogenesis, and/or myotube function
(Additional file 1: Figure S2J). However, silencing the ex-
pression of these genes in our primary muscle cells only
affected a few studied phenotypes (Additional file 1:
Figure S2K, L).
Impact of obesity on the DNA methylation pattern during
differentiation of primary human myoblasts into
myotubes
Although recent studies suggest that obesity impairs myo-
genesis in rodents, there is limited data from myoblast
differentiation in obese humans [37]. We therefore investi-
gated whether obesity affects the DNA methylation pat-
tern during differentiation of primary human myoblasts
into myotubes. The DNA methylation data described
above in healthy non-obese subjects were compared with
data from myoblasts and differentiated myotubes from 14
obese subjects (BMI > 30 kg/m2; Fig. 1a). The clinical
characteristics of these subjects are presented in Table 1.
(See figure on previous page.)
Fig. 4 Silencing of IL32 influences differentiation capacity and insulin signaling whereas IL32 overexpression in mice impairs insulin sensitivity.
a Array data of mRNA expression and DNA methylation (only significant sites) of IL32 before versus after differentiation of primary human
myoblasts from non-obese subjects (n = 13, *q < 0.05). b Protein expression of IL-32 in primary human myoblasts (0 h) and after 3 and 7 days of
differentiation. Stain-free total protein staining was used for normalization. A representative blot is shown above the bars (n = 7). c Increased
protein level of IL-32 found during differentiation was significantly blocked with siRNA after 3 and 7 days of differentiation of myoblasts. The
average of Si-SCR is set to 1 at both time points. Stain-free total protein staining was used for normalization. Representative blots are shown
above the bars. d Significantly enriched gene sets in Gene Set Enrichment Analysis (GSEA) based on differential gene expression in IL-32 deficient
myotubes (day 7) versus control (si-SCR). Lower panels show expression of genes contributing to the gene sets Hypertrophic Cardiomyopathy HCM
and Pentose Phosphate Pathway (n = 5, *q < 0.05). e A number of genes involved in myogenesis and metabolism with significantly different expression
between IL-32 deficient myotubes (day 7) and control (n = 5, *q < 0.05). Silencing of IL32 was associated with increased levels of ATP (f) and increased
insulin-stimulated AKT phosphorylation at Ser473 and Thr308 (n = 3) (g) in differentiated myotubes (day 7). h The expression of IL32 in skeletal muscle
biopsies obtained from 27 adult men correlated positively with HOMA-IR (Pearson correlation). i Experimental set-up of the mouse study with IL32tg
mice showing the duration of HFD, including time points for different analyses. j There was no difference in body weight between IL32tg and WT mice
after 18 weeks on a HFD. IL32tg mice had significantly lighter tibialis anterior in absolute value (k) and in relation to body weight (l) compared to WT
after 18 weeks on a HFD. IL32tg mice had lower glucose levels in the fasted state and higher levels 20 minutes after intravenous insulin
administration compared with WT (m), resulting in a decreased insulin response (n). o Significantly enriched gene sets in GSEA based on differential
gene expression in tibialis anterior from IL32tg versus WT mice after 18 weeks on a HFD (n = 6). p Soleus from IL32tg mice have decreased Akt
phosphorylation at Thr308 after 30 minutes in vitro incubation with or without insulin (WT n = 4, IL32tg n = 5). Data are presented as mean ±
SEM, n = 4 for cell experiments, n = 10 for WT mice, and n = 9 for IL32tg mice if nothing else stated. WT, Wild type mice (control); IL32tg, IL32
transgenic mice; HFD, High fat diet; * P < 0.05, ** P < 0.01, *** P < 0.001 for figure b and e–o. Statistics were calculated with paired t-test for cell
experiments and Mann–Whitney U test for mice data
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Obese subjects had increased fat mass and insulin resist-
ance estimated by HOMA-IR, as well as decreased HDL
levels and VO2max, demonstrating a marked lower aerobic
fitness level, compared with healthy non-obese subjects.
The average degree of DNA methylation was not signifi-
cantly different between obese and non-obese subjects,
neither in myoblasts nor in myotubes. Accordingly, the
global methylation level increased in the same gene and
CpG island regions in both obese and non-obese subjects
after differentiation (Additional file 1: Figure S3A). How-
ever, among obese subjects, we identified 147,161 individ-
ual CpG sites with significantly altered DNA methylation
in myoblasts versus myotubes (q < 0.05, Additional file 6:
Table S5), which is approximately 3.7 times more than for
non-obese subjects (Pχ2 < 0.001) where 39,572 CpG
sites changed significantly during myogenesis (Fig. 1a).
103,829 (71%) of the significant sites in obese subjects
had increased methylation and 43,332 (29%) had decreased
methylation in myotubes compared with myoblasts
(Additional file 1: Figure S3B).
The overlap of significantly changed CpG sites be-
tween the obese and non-obese groups was 27,388 for
sites with increased methylation and 1645 for sites with
decreased methylation (Fig. 5a), revealing a large num-
ber of CpG sites uniquely methylated/demethylated in
either of the groups during myogenesis (Additional file 7:
Table S6). Significant pathways enriched for all differen-
tially methylated genes in obese subjects are presented in
Table 2.
We proceeded to identify unique genes where the
methylation level only changed in obese or non-obese
subjects during myogenesis. Here, one needs to take into
account that different CpG sites in the same gene can
change in the obese and/or non-obese subjects during
differentiation, but this still represents the same gene in
both groups. Thus, 5837 unique genes were differentially
methylated during myogenesis only in the obese. Inter-
estingly, these genes were significantly enriched in gene
ontology (GO)-biological processes related to the im-
mune response (Fig. 5b and Additional file 7: Table S6).
The fact that epigenetic regulation is abnormal in cells
from obese subjects, even after culturing them in the
same condition as cells from non-obese subjects, dem-
onstrates an altered epigenetic memory in muscle stem
cells due to obesity. Methylation of 170 unique genes
changed only in non-obese, but no enriched GO-
biological process was found for these genes. To get a
better view of where in the genome significant changes
in methylation took place, the number of significant sites
for each gene region was compared with the total num-
ber of analyzed sites for each region. In both obese and
non-obese subjects, a higher proportion of significant
sites than expected was observed in areas close to
promoter regions, TSS, and CpG islands (Pχ2 < 0.001;
Fig. 5c). Nevertheless, obese subjects had a lower pro-
portion than non-obese in TSS1500, TSS200, 5’UTR, 1st
exon, and CpG islands as well as a higher proportion in
the gene body, 3’UTR, intergenic region, shelves, and
open sea (Pχ2 < 10
−11). Additionally, 33,854 (23%) of the
significant CpG sites in obese subjects were annotated
to enhancer regions (Fig. 5c), which is significantly more
than expected (Pχ2 < 10
−104). In non-obese subjects,
there were 10,194 (26%) significant CpG sites annotated
to enhancer regions, which is also more than expected
(Pχ2 < 10
−125) and a higher proportion than in obese sub-
jects (Pχ2 < 10
−29). The overrepresentation of significant
CpG sites located in enhancer regions suggests that
DNA methylation impacts on gene transcription during
myogenesis.
Regarding non-CpG methylation in the obese, also
here the number of significant sites was more than in
non-obese subjects; 822 non-CpG sites (82%) had signifi-
cantly changed methylation after differentiation (Additional
file 6: Table S5).
Impact of obesity on the transcriptome during
differentiation of primary human myoblasts into
myotubes
We proceeded to investigate if obesity affects the gene ex-
pression pattern during differentiation of primary human
myoblasts into myotubes. Here, we compared the gene ex-
pression data described above in non-obese subjects with
that of myoblasts and differentiated myotubes from 13
obese subjects (BMI > 30 kg/m2). The expression level of
7362 transcripts corresponding to 6080 unique genes
changed significantly before versus after differentiation in
obese subjects (Additional file 8: Table S7), which is
slightly less than in non-obese subjects (Fig. 1a). 40% of
the significantly changed transcripts in obese subjects
were upregulated and 60% were downregulated. Of note,
all identified MRFs, MLCs, and MHCs with differential
expression in non-obese subjects also changed in the same
direction in the obese (Fig. 2a, e and Additional file 8:
Table S7), except forMYL5, which was significantly upreg-
ulated only in non-obese subjects.
GSEA of differentially expressed genes in obese subjects
resulted in 15 downregulated gene sets and 17 upregulated
gene sets (Additional file 8: Table S7). While all enriched
gene sets for obese were also enriched for non-obese sub-
jects, a number of upregulated gene sets including tight
junctions, calcium signaling, and metabolism of various
fatty acids as well as two downregulated gene sets –
galactose metabolism and drug metabolism, other en-
zymes – were only enriched in the non-obese (Fig. 2b, c
and Additional file 3: Table S2), suggesting that partial loss
of muscle cell function occurs in obese humans.
Interestingly, we identified numerous unique changes
in expression during myogenesis between obese and
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Fig. 5 Differences in DNA methylation and gene expression before versus after differentiation of human primary myoblasts of obese and non-obese
subjects. a Overlap of significant CpG sites with decreased and increased DNA methylation, respectively, after differentiation of human primary
myoblasts of non-obese (n = 14) and obese (n = 14) subjects. b Significantly enriched gene ontology (GO)-terms (q < 0.05) of genes that exhibit
differential DNA methylation only in obese. c Distribution of significant CpG sites that showed differential DNA methylation during myogenesis in
non-obese and obese subjects compared with all analyzed CpG sites on the array and also between non-obese and obese in relation to gene regions,
CpG island regions, and enhancer-regions. * Pχ2 < 0.05 compared with all analyzed, # Pχ2 < 0.05 between non-obese and obese subjects. d Overlap of
downregulated and upregulated genes during myogenesis between non-obese (n = 13) and obese subjects (n = 13). Networks of certain genes
only differentially expressed during myogenesis in obese (e) and non-obese (f) subjects, respectively, and related GO-terms to these genes. Green,
downregulated; red, upregulated. Node size is based on expression fold change. g Genes (different probes) regulated in opposite directions during
myogenesis in non-obese and obese subjects (* q < 0.05). h The top graph shows mRNA expression of genes only differentially expressed and
methylated in obese subjects during myogenesis that are associated with DNA methylation, obesity, and/or metabolic disorders as well as myogenesis
and/or myopathies. Values are presented as log2 to reduce magnitude and better visualize expression of all genes grouped in each category in one
graph. The lower graph shows DNA methylation of significant CpG sites annotated to genes with a red box in the top graph (* q < 0.05). i Significant
enrichment of the number of CpG sites within obesity candidate genes with differential DNA methylation at P < 0.05 between non-obese and obese
subjects in myoblasts and myotubes, respectively (* Pχ2 < 0.05). Data are presented as mean ± SEM
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non-obese subjects, i.e., 1151 genes were only differen-
tially expressed in obese and not in non-obese subjects,
while 1376 genes only changed expression in the non-
obese (Fig. 5d and Additional file 9: Table S8). Addition-
ally, 2746 downregulated genes and 2191 upregulated
genes after differentiation were overlapping between
obese and non-obese subjects.
We next used GeneMANIA Cytoscape [38, 39] to
visualize enriched biological processes associated with
genes that only changed expression in either obese or
non-obese subjects. Several GO-terms related to oxidative
phosphorylation and an IL-1 response were significant
only for obese subjects (Fig. 5e and Additional file 9: Table
S8), whereas many GO-terms related to insulin signaling
and glucose homeostasis were significant only for non-
obese subjects (Fig. 5f and Additional file 9: Table S8). In
contrast, GO-terms related to, e.g., the cell cycle, antigen
recognition, and protein turnover were significant for both
the unique genes found in either the obese or non-obese
(Additional file 9: Table S8), suggesting a potential com-
pensatory mechanism between genes uniquely regulated
in the two groups. Interestingly, we also identified two
genes, PTP4A2 and PDCD7, which were significantly up-
regulated in the obese, while significantly downregulated
in the non-obese during myogenesis (Fig. 5g). In contrast,
PSMA1, ST3GAL3, and C11orf58 (SMAP) were down-
regulated in obese while upregulated in non-obese
subjects (Fig. 5g). Collectively, these data support
metabolic and inflammatory disparities between differ-
entiating muscle stem cells isolated from obese and
non-obese subjects.
Overlapping differences in DNA methylation and mRNA
expression during differentiation in obese versus
non-obese subjects
In obese subjects, 5197 genes showed both differential
expression and differential DNA methylation of one or
more CpG site(s) in myoblasts compared with myotubes
(Table 4 and Additional file 10: Table S9). Interestingly,
220 of these genes did not show differential expression
nor methylation in non-obese subjects and have been
implicated in myopathies, epigenetic regulation, and
metabolic conditions such as obesity and cardiovascular
disease (Additional file 11: Table S10). Some of the
genes, including MECP2, ENHO, IL18, and PLCB1, are
presented in Fig. 5h. Furthermore, four genes (MED10,
NBPF11, PMAIP1, and ZFAND2A) had differential ex-
pression together with differential methylation in non-
obese subjects, but were not differentially expressed nor
differentially methylated in obese subjects (Additional file
11: Table S10). These findings further emphasize an ab-
normal epigenetic regulation during differentiation of
muscle stem cells from obese subjects potentially reflect-
ing an impaired metabolism in vivo.
We then performed correlation analyses between the
expression and methylation of corresponding CpG sites
for the 5197 genes that had significant differences in
both expression and methylation in obese subjects
(Additional file 10: Table S9). Here, we found 3515
and 4014 correlations between expression and methyla-
tion in myoblasts and myotubes, respectively (Additional
file 10: Table S9), which is more than expected by chance
(2351 correlations with P < 0.05).
Differential DNA methylation and gene expression in
myoblast and/or myotubes between obese and
non-obese subjects
We further tested if any individual CpG sites were
differentially methylated when comparing myoblasts be-
tween obese and non-obese or when comparing myotubes
between obese and non-obese, respectively. While 29,337
CpG sites were differentially methylated in myoblasts
from obese versus non-obese at P < 0.05, only methylation
of two CpG sites (near ZNF629 and SDCCAG1) were sig-
nificantly different based on FDR < 5% (Additional file 12:
Table S11). In myotubes, 28,884 sites were differentially
methylated between obese and non-obese subjects at
P < 0.05, but none had FDR < 5%. Nevertheless, we pro-
ceeded to test if there was an over-representation of iden-
tified CpG sites with P < 0.05 in/near known candidate
genes for obesity based on discoveries in genome-wide as-
sociation studies (P < 1.0 × 10−5; www.genome.gov/gwas-
tudies accessed 22 August 2012). Out of 3472 analyzed
CpG sites annotated to 129 candidate genes for obesity,
273 CpG sites in 93 genes had differential methylation in
obese versus non-obese at P < 0.05 in myoblasts and 253
CpG sites in 86 genes had P < 0.05 in myotubes (Fig. 5i
and Additional file 12: Table S11). This is more than ex-
pected by chance (myoblasts; Pχ2 = 2.3 × 10
−5, and myo-
tubes; Pχ2 = 0.001), thus suggesting that epigenetic
variation may influence the genetic risk for metabolic dis-
orders [40]. We continued to compare the transcriptome
profile in myoblasts and myotubes from obese versus
non-obese subjects. After FDR correction, there were no
significant differences in gene expression between obese
and non-obese subjects in myoblasts nor in myotubes.
Neither did we find any enrichment of candidate genes for
obesity among the genes with altered expression at
P < 0.05 between obese and non-obese subjects in myo-
blasts or myotubes.
Enzymes regulating DNA methylation in obese and
non-obese subjects
To further assess why methylation of approximately 3.7
times more sites changed in obese compared with non-
obese subjects during differentiation, we analyzed the
expression of all three catalytically active DNA methyl-
transferases (DNMTs) with qPCR at three different time
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points, in myoblasts and after 2 (intermediate) and 7
(myotubes) days of differentiation (Fig. 6a). Interestingly,
DNMT1 expression was only significantly upregulated in
obese, but not in non-obese subjects, after 2 days of dif-
ferentiation. The significant changes in the expression
patterns for DNMT3A and DNMT3B were similar in
obese and non-obese subjects (Fig. 6a).
We next silenced DNMT1 to further study its role
during myogenesis (Additional file 1: Figure S2B) and re-
duced mRNA and protein levels were achieved after 3
and 7 days of differentiation (Fig. 6b). This resulted in
reduced expression of two cell cycle regulators, cMYC
and JUNB, after 3 days, as well as increased expression
of the myogenic marker MYOD1 and decreased ATP
levels after 7 days, of differentiation (Fig. 6c–e). Hence,
DNMT1 seems to affect myogenesis and cell function.
Differences in DNA methylation could potentially also
be explained by differences in the availability of methyl
groups or other epigenetic modifiers. Notably, the ex-
pression pattern of 10 enzymes and modifiers involved
in the one carbon metabolism and generation of the me-
thyl donor S-adenosylmethionine changed significantly
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Fig. 6 DNMT1, DNMT3A, and DNMT3B during differentiation of primary human myoblasts. a mRNA expression of DNMT1, DNMT3A, and DNMT3B
in myoblasts, after 2 days of differentiation (intermediate) and in differentiated myotubes from six non-obese and six obese subjects. b siRNA
silencing of DNMT1 in the myoblasts was confirmed after 3 and 7 days of differentiation at mRNA and protein levels. The average of Si-SCR is set
to 1 at both time points for protein expression. Stain-free total protein staining was used for normalization. Representative blots are shown above
the bars. Silencing of DNMT1 resulted in reduced expression of cMYC and JUNB after 3 days of differentiation (c) as well as increased expression
of MYOD1 (n = 7) (d) and reduced levels of ATP (n = 3) in myotubes (day 7) (e). Data are presented as mean ± SEM, n = 4 for (b–e) if nothing else
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in either the obese and non-obese during differentiation
(Additional file 1: Figure S3C). These differences may
also contribute to the abnormal methylation changes
seen in the obese, i.e., that approximately 3.7 times more
CpG sites changed in obese compared with non-obese
subjects during myogenesis.
Secretion of cytokines and growth factors from myoblasts
and myotubes of obese and non-obese subjects
Extracellular stimuli, like circulating cytokines and
growth factors, influence myogenesis [4], and their se-
cretion may be altered by obesity. We therefore analyzed
the secretion of CCL2, TGF-β3, IL-32, IL-6, and TNF-α,
all previously implicated in myogenesis (except IL-32)
[41], in the culture media from myoblasts and myotubes
of obese and non-obese subjects.
As expected, the secretion of CCL2 increased after dif-
ferentiation in non-obese and correlated with its corre-
sponding mRNA level in myoblasts (Additional file 1:
Figure S3D). The same secretion pattern was seen for the
obese. TGF-β3 was the cytokine with highest fold-change
in mRNA expression between myoblasts and myotubes in
both obese and non-obese subjects (Additional file 1:
Figure S3E). However, significantly increased TGF-β3 se-
cretion after differentiation was only observed in the obese
(Additional file 1: Figure S3E). Thereby, we also identified
a secretory discrepancy between myotubes generated from
muscle stem cells of obese and non-obese subjects, al-
though cultured under the same condition. IL-32 could
not be detected in culture media from myoblasts (Add-
itional file 1: Figure S3F), which is in agreement with the
IL-32 data presented above (Fig. 4a, b). However, we could
detect IL-32 secretion from myotubes from 46% of the
non-obese and 20% of the obese subjects, suggesting that
IL-32 may be a myokine. However, there was no signifi-
cant difference in secretion levels between the obese and
non-obese (Additional file 1: Figure S3F). No differences
in secretion of IL-6 and TNF-α were detected (data not
shown).
Technical and biological validation
We finally tested if our microarray data could be technic-
ally and biologically validated. For technical validation, we
compared our mRNA microarray data with qPCR data
generated from the same samples for DNMT1 and found
significant correlations between the microarray and qPCR
data (r = 0.57, P = 0.002). For biological validation, we
compared our microarray data for IL32 and ARPP21 with
qPCR data generated in a different set of cells cultured at
different time points. Importantly, we found the same
changes in the expression pattern for these two genes in
cell culture experiments performed at different time
points (Fig. 4a, Additional file 1: Figure S2A and D–E).
Discussion
This study highlights the importance of genome-wide
epigenetic changes during human myogenesis. We found
numerous epigenetic and transcriptional alterations dur-
ing differentiation of primary human muscle stem cells.
Importantly, we identified IL-32 as a novel factor influ-
encing myogenesis and insulin sensitivity. Moreover, we
observed abnormal epigenetic changes and gene
expression patterns during differentiation of human
muscle stem cells from obese compared with non-obese
subjects.
Here, we present the first study analyzing the genome-
wide DNA methylation and gene expression patterns
during differentiation of activated primary muscle stem
cells isolated from a large human cohort including both
obese and non-obese subjects. We observed overwhelm-
ing de novo methylation during myogenesis, supporting
DNA methylation as an important epigenetic mechanism
coordinating cell-specific gene expression as the cells be-
come more specialized. Importantly, myogenesis was ac-
companied by dynamic methylation and expression
changes of PAX7, all major MRFs and MEF2s (MYOD,
MYF5, MYOG, MYF6, MEF2A, MEF2C, MEF2D), the
MHC and MLC families, as well as mitochondrial pro-
teins, thereby demonstrating that the cells were success-
fully differentiated. Moreover, GSEA of genes differentially
expressed following differentiation showed downregula-
tion of gene sets involved in the cell cycle and DNA syn-
thesis, reflecting that the myoblasts go into cell cycle
arrest and start to differentiate. Upregulated gene sets re-
flect myofiber formation (e.g. hypertrophic cardiomyop-
athy, cardiac muscle contraction, and calcium signaling
pathway) and support that the myotubes line up close to
each other (extracellular matrix receptor interaction and
cell adhesion), which can also be seen in the pictures of
our differentiated myotubes. Interestingly, the GSEA re-
vealed a major shift in metabolism and substrate choice,
with the myoblasts having higher expression levels of gene
sets regulating fructose, mannose and galactose metabol-
ism, and the pentose phosphate pathway and the myo-
tubes having higher expression levels of gene sets
regulating fatty acid metabolism as well as tryptophan and
linoleic acid metabolism. Altogether, this proposes a shift
from using carbohydrates as fuels in dividing myoblasts
towards using fatty acids and amino acids as fuels and
building blocks in mature myotubes. This is in accordance
with a recent study showing that activated satellite cells
(myoblasts) rely on glycolysis [42]. Ryall et al. [42] further
describe how a shift in metabolic substrate utilization,
partly through histone modifications, regulates cell devel-
opment and cell fate, a process termed ‘metabolic repro-
gramming’. In our study, numerous changes in DNA
methylation induced by differentiation accompany the
shift in expression of gene sets regulating metabolism,
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thereby suggesting a close interaction between epigenetic
modifications and metabolism during myogenesis.
Interestingly, two pregnancy-associated gene families,
PSGs and CGBs, were among the most downregulated
gene groups characterizing the transition from myoblast
to myotube. The PSGs are glycoproteins secreted by the
placental trophoblasts into the maternal bloodstream
during pregnancy and are associated with fetal well-
being [29]. The CGBs are also secreted by the placental
trophoblasts with the purpose of maintaining the corpus
luteum during pregnancy [30]. Neither the PSGs nor
CGBs have ever been detected or described in relation
to skeletal muscle, myoblasts, or myogenesis. However,
from our studies, it seems as if they could have a major
impact on human myoblast regulation. Another preg-
nancy associated protein, leukemia inhibitory factor,
which is normally also expressed by trophoblasts to
facilitate implantation, has in two decades been known
to stimulate proliferation of myoblasts [43], was tested
for its effect of myoblast transplantation in animals [44],
and has been shown to be secreted from myoblasts [45].
These findings indicate possible secretory similarity be-
tween trophoblasts and myoblasts. Another interesting
gene group downregulated during myoblast differenti-
ation is the metallothioneins, which also showed dy-
namic changes in DNA methylation during myogenesis.
They have been sparsely described in relation to skeletal
muscle, but appear to increase in atrophying muscles
[46] and might be related to a high requirement of zinc
for metabolic activities during the early stage of myo-
blast differentiation [47].
In addition to the identified novel gene groups
described above, a number of unique genes displayed
transcriptional and epigenetic changes, and could thus
potentially be involved in regulating myogenesis and
muscle function. We selected some of these novel candi-
date genes, including IL32, which was dramatically up-
regulated during differentiation, for functional follow-up
experiments. By combining in vitro and in vivo experi-
ments, IL-32 was found to have negative effects on both
myogenesis and insulin sensitivity in mice and humans.
Silencing IL32 in human myotubes increased insulin-
stimulated AKT phosphorylation and intracellular ATP
levels. These cells also had increased expression of
OXPHOS genes and PPARGC1A, which is in line with
changes seen in muscle during exercise [48, 49]. To fur-
ther explore this relationship in vivo, we studied mice
overexpressing human IL32 and fed a HFD. IL32tg mice
responded less well to insulin, which resulted in higher
glucose levels, had lower insulin-stimulated Akt phos-
phorylation in soleus, and decreased OXPHOS gene ex-
pression in tibialis anterior, supporting our in vitro data.
We could not detect any alteration in ATP levels in
soleus muscle from IL32tg mice, which may reflect that
the phenotype is more pronounced in some muscle
types or in pure muscle cells. Remarkably, we also found
a negative association between muscle-derived IL32
levels and whole body insulin sensitivity in humans in
vivo. Our experiments further suggest that IL-32 has
negative effects on myogenesis and muscle growth/
maintenance by inhibiting expression of myogenic genes,
potentially through reduced AKT signaling. For example,
the expression of MEF2C, MYOD1, and DMD was
higher in IL-32-deficient myotubes and IL32tg mice had
decreased muscle mass. Upregulation of IL-32 during
myogenesis may therefore function to inhibit muscle
overgrowth. Even if muscle function and mass is of great
importance for a good quality of life, the tissue is meta-
bolically expensive. It may therefore have been evolu-
tionary beneficial for survival to develop mechanisms
that control muscle growth and reduce insulin sensitivity
[50], while with the modern lifestyle it contributes to
disease. Interestingly, several of the effects of IL-32 on
muscle cells resemble those of myostatin, a master regu-
lator of muscle growth. Myostatin is a myokine, which
increases during myogenesis, signals through the TGF-β
pathway, and regulates myoblast differentiation [51, 52].
Increased expression of myostatin is associated with
muscle wasting, while its knockdown causes hyper-
trophy. One of the mechanisms by which myostatin ex-
erts its function is through reduced AKT
phosphorylation. It also seems to regulate glucose
utilization and its expression is positively correlated with
insulin resistance [53]. Myostatin inhibitors have been
intensively studied as pharmaceutical targets for muscle
atrophy and mice treated with anti-myostatin antibodies
have increased muscle mass and improved muscle insu-
lin sensitivity [54]. In conclusion, our findings suggest
that IL-32 resembles myostatin in several ways, warrant-
ing future studies on whether IL-32 inhibitors may im-
prove muscle mass and function. We also demonstrate,
for the first time, that IL-32 is secreted from myotubes,
further encouraging studies of its function in muscle
biology.
DNA methylation was initially considered a silencing
mark. However, more recent data show that the impact
of methylation on expression varies with genomic con-
text and methylation may both negatively and positively
affect the transcriptional activity, regulating splicing and
use of alternative promoters [33]. For example, the IL32
promoter does not reside in a CpG island and increased
methylation may therefore be observed together with in-
creased expression. While large absolute changes in
DNA methylation are observed in cancer cells, modest
methylation changes are commonly seen in non-
tumorigenic cells [17, 18, 55]. Nevertheless, the effects
may still be of biological relevance, particularly in com-
plex diseases where numerous changes with smaller
Davegårdh et al. BMC Medicine  (2017) 15:39 Page 23 of 27
effect sizes are known to affect disease susceptibility
[56]. Here, we found both negative and positive correla-
tions between expression and methylation for numerous
genes in both myoblasts and myotubes, emphasizing the
complexity of epigenetic regulation of expression as
mentioned above. The luciferase assay further showed
that increased promoter methylation directly influences
the transcriptional activity of MCM10, whose expression
and methylation changed during myogenesis.
Obesity is a complex, multifactorial disorder rapidly in-
creasing worldwide. Although interactions between genetic
and environmental factors are known to affect a person’s
susceptibility to weight gain, identified genetic variants do
only explain a modest proportion of the estimated herit-
ability of obesity and related diseases [56]. This has re-
sulted in a growing interest in understanding the role of
epigenetics in the increasing prevalence of obesity. Indeed,
obesity, overfeeding, physical activity, and genetic variation
have been shown to alter the genome-wide DNA methyla-
tion pattern in human adult tissues [17, 18, 57–61]. How-
ever, current knowledge about the impact of obesity on the
epigenetic pattern during differentiation of human stem
cells remains scarce.
The novel observation of altered epigenetic and tran-
scriptomic regulation during differentiation of myoblasts
isolated from obese individuals shows that muscle stem
cells are profoundly altered/programmed by the systemic
nutritional environment and/or physical inactivity. Al-
though the muscle stem cells from obese and non-obese
subjects were cultured during identical conditions, the
number of DNA methylation changes induced by differen-
tiation was three-fold higher in the obese. This clearly
demonstrates a different epigenetic reorganization during
the transition from myoblast to myotube as a memory of
the obese environment. DNMT1 is a methyltransferase
known to maintain methylation during replication, but has
also been found to affect de novo methylation during cell
differentiation [62, 63]. Hence, the more active de novo
methylation observed in cells from obese may be explained
by the increased DNMT1 expression in early myogenesis.
We further silenced DNMT1 throughout myogenesis
and found decreased levels of cMYC and JUNB at day
3 of differentiation as well as increased MYOD1 ex-
pression in differentiated myotubes, suggesting that
DNMT1 may also affect the cell cycle and differenti-
ation in these cells.
While approximately three times more methylation
changes took place in the obese during differentiation,
only a modest number of differences were observed in
myoblasts from obese versus non-obese subjects. It may
be explained by large variances within groups. Indeed,
the phenotype of a complex disease is commonly caused
by a combination of many small variations at numerous
loci that require large cohorts for detection [64].
A surprisingly large number of genes were uniquely
changed in expression either in obese cells (1151) or non-
obese cells (1376) after differentiation, underscoring that
both DNA methylation and gene expression changes vary
genome-wide between the two cell populations. Interest-
ingly, several genes that only showed expression changes in
the non-obese are known to regulate insulin signaling and
glucose homeostasis. Indeed, the obese subjects included
in this study were insulin resistant and had lower oxidative
capacity based on VO2max. Among the genes that showed
both differential gene expression and methylation in only
obese, were genes previously associated with dysfunctional
myogenesis, e.g., PLCB1 and CDK9 [65, 66], genes linked
to obesity or other metabolic diseases, including IL18,
PNPLA2, and ENHO [67–69], as well as genes for which
an association to obesity has never been described. The lat-
ter may be interesting targets to study further in relation to
obesity and myogenesis. Of interest are also five genes that
were regulated in opposite direction in obese compared
with non-obese. One of these, PSMA1 has previously been
associated with fatty liver in obese subjects [70]. Addition-
ally, PTP4A2 was recently implicated in hematopoietic
stem cell self-renewal [71] and PDCD7 encodes a compo-
nent of the spliceosome [72].
Conclusions
This study provides a comprehensive map of the dynamic
methylome and transcriptome during differentiation of
human muscle stem cells and identified numerous of new
myogenic targets. Importantly, we showed that IL-32 is a
novel candidate influencing human myogenesis and insu-
lin sensitivity both in vivo and in vitro. Our data further
highlight that the metabolic environment influences the
epigenetic memory in human muscle stem cells, thereby
altering the transcriptome and epigenome during adult
myogenesis in obese individuals.
Additional files
Additional file 1: Supplemental methods. Table S12. Antibodies used
for western blot. Figure S1. Characterization of the primary human
myoblasts. Figure S2. Silencing of ARPP21, SMAD6, and PLAC8 during
differentiation of primary human myoblasts. Figure S3. Differences in
methylation, transcription, and secreted cytokine levels before versus
after differentiation of primary human myoblast from obese and
non-obese subjects. (PDF 1126 kb)
Additional file 2: Table S1. CpG sites and non-CpG sites that exhibit
differential DNA methylation (q < 0.05) before versus after differentiation
of human primary myoblasts of 14 non-obese subjects, as well as
enriched KEGG pathways (adjusted P < 0.05) of the genes annotated to
these significant CpG sites (mean ± SD). (XLSX 3195 kb)
Additional file 3: Table S2. Differentially expressed genes (q < 0.05)
before versus after differentiation of human primary myoblasts of 13
non-obese subjects, as well as significant results of gene set enrichment
analysis (FDR adjusted P < 0.05) and JASPAR motif search (PBonferroni < 0.05)
for these genes (mean ± SD). (XLSX 669 kb)
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Additional file 4: Table S3. Genes with overlapping changes in gene
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